Weather New York, NY +68°F

Actavis Plc

Staphylococcus Epidermidis SEM

Iterum Therapeutics Ltd., Raised $40 Million in Series A For Licensure and Development of Anti-Infective Drug

Iterum Therapeutics Ltd. secured $40 million in Series A funding led by Frazier Healthcare Partners together with other venture capitalists. The said fund will be used to acquire license and to enhance the development of the anti-infective drug that could counter certain bacteria's resistance to antibiotic.

Read Full Article
Valeant Pharmaceuticals International Inc.

Valeant to drop deal-making in near term to cut debt, boost stock

Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.

Read Full Article
A sample of Botox

Allergan agrees to $66 billion Actavis offer; Valeant walks

Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

Read Full Article
David Pyott

Allergan near buyout of up to $65 billion to escape Valeant, Ackman: source

Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.

Read Full Article
Sanofi

Actavis, Sanofi among bidders for Omega Pharma

Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV [COUCKO.UL], Bloomberg reported, citing people familiar with the matter.

Read Full Article
A sample of Botox

Actavis plans new merger approach for Allergan - sources

Actavis Plc (ACT.N) plans to approach Allergan Inc (AGN.N) again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics